Table 1.
Baseline and clinical characteristics at time of PH diagnosis.
| Treated SAPH (n = 38) | Untreated SAPH (n = 20) | |
|---|---|---|
| Age (years) | 57.9 ± 9.4 | 55.0 ± 6.8 |
| Gender | ||
| Female, n (%) | 23 (60.5) | 8 (40.0) |
| Male, n (%) | 15 (39.5) | 12 (60.0) |
| Weight (kg) | 77.3 ± 20.9 | 79.8 ± 11.6 |
| Race | ||
| Black, n (%) | 32 (84.2) | 14 (70.0) |
| White, n (%) | 4 (10.5) | 3 (15.0) |
| Other, n (%) | 2 (5.3) | 3 (15.0) |
| Smoking history, n (%) | 20 (52.6) | 11 (55.0) |
| Diastolic dysfunction, n (%) | 12 (31.6) | 4 (20.0) |
| Systolic dysfunction, n (%) | 3 (7.9) | 2 (10.0) |
| Kidney disease, n (%) | 21 (55.2) | 9 (45.0) |
| Liver disease, n (%) | 5 (13.1) | 1 (5.0) |
| Diabetes, n (%) | 10 (26.3) | 3 (15.0) |
| Additional lung disease/concurrent COPD, n (%) | 18 (47.4) | 5 (25.0) |
| Extrapulmonary sarcoidosis, n (%) | 9 (23.7) | 5 (25.0) |
| Oxygen requirement (L/min) | 3.3 ± 2.9 | 2.8 ± 2.7 |
| Prednisone dose (mg) | 9.5 ± 8.6 | 12.1 ± 6.2 |
| Additional anti‐inflammatory treatment | ||
| Methotrexate, n (%) | 13 (34.0) | 9 (45.0) |
| Other agents, n (%) | 5 (13.0) | 4 (20.0) |
| Anti‐fibrotic Therapy, n (%) | 1 (2.6) | 0 (0.0) |
| RA Pressure (mmHg) | 8.4 ± 4.4 | 6.9 ± 2.7 |
| PA systolic (mmHg)* | 58.5 ± 15.5 | 49.3 ± 10.5 |
| mPAP (mmHg)* | 36.3 ± 8.7 | 31.4 ± 5.9 |
| PCWP (mmHg) | 9.5 ± 5.5 | 11.0 ± 4.1 |
| PVR (Woods units)* | 6.6 ± 3.2 | 3.8 ± 1.3 |
| CI (L/min/m2) | 2.5 ± 0.6 | 2.9 ± 0.9 |
Note: Continuous variables are presented as mean and standard deviation. Statistical comparison of each variable between treated SAPH and untreated SAPH groups yielded p > 0.05. All patients with additional lung disease had chronic obstructive pulmonary disease (COPD). All patients were on prednisone.
Abbreviations: CI, Cardiac Index; COPD, chronic obstructive pulmonary disease; mPAP, mean pulmonary artery pressure; PA, pulmonary artery; PH, pulmonary hypertension; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RHC, right‐heart catheterization; SAPH, sarcoidosis‐associated pulmonary hypertension.
*p < 0.05.